38
total announcements
ALKEM.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 21 Oct 2026
Market Cap
₹59,830 Cr
P/E (TTM)
27.7
P/E (Forward)
22.4
EPS (TTM)
₹180.44
52W Low
₹4,975.50
52W High
₹5,933.50
Dividend Yield
0.40%
Beta
0.29
Price / Book
4.3
Debt / Equity
14.3
Revenue (TTM)
₹15,081 Cr
Gross Margin
64.80%
Operating Margin
17.80%
Alkem Laboratories Limited
Alkem Laboratories Limited has informed the Exchange regarding the appointment of Mr. Rajpal Singh Rana as a senior management personnel, effective from 03rd August, 2026. The details of the appointment are provided in Annexure I to the letter.
Alkem Laboratories Limited
Alkem Laboratories Limited has dispatched letters to shareholders who have not registered their email addresses with the company or depository participants, providing the web-link to access the Annual Report for FY 2025-26.
Alkem Laboratories Limited
Alkem Laboratories Limited has informed the Exchange about the dispatch of Notice of the 52nd Annual General Meeting (AGM) along with the Annual Report for the financial year 2025-26 and e-voting information.
Alkem Laboratories Limited
Alkem Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 27, 2026, along with the Annual Report for financial year 2025-2026.
Alkem Laboratories Limited
Alkem Laboratories Limited has informed the Exchange about the Business Responsibility and Sustainability Report for the financial year ended 31st March, 2026.
Alkem Laboratories Limited
Alkem Laboratories Limited has scheduled a conference call on August 14, 2026, to discuss its Q1FY27 financial results.
Alkem Laboratories Limited
Alkem Laboratories Limited has informed the Exchange regarding the resignation of Dr. Jitendra Singh Huda as a Senior Management Personnel effective July 23, 2026.
Alkem Laboratories Limited
Alkem Laboratories has completed the acquisition of at least 51% of Occlutech Holding AG, a Swiss company, through its subsidiary Alkem Medtech Private Limited.
Alkem Laboratories Limited
Alkem Laboratories Limited has informed the Exchange about a copy of newspaper publication regarding the notice of the meeting of the equity shareholders of Alkem Laboratories Limited being convened pursuant to the order of the Hon’ble National Company Law Tribunal, Mumbai Bench, dated June 10, 2026. The meeting will be held on August 17, 2026, through electronic mode (video conference or other audio visual means) to consider and if thought fit, approve the Scheme of Amalgamation between Adroit Biomed Limited and Alkem Laboratories Limited.
Alkem Laboratories Limited
Alkem Laboratories Limited has acquired 79,36,50,794 equity shares of Alkem Medtech Private Limited at Rs. 13.86 per share, aggregating to Rs. 11,00,00,00,005/-. The acquisition is a rights issue and the shares were allotted on 15th July, 2026.
Alkem Laboratories Limited
Alkem Laboratories Limited has informed the Exchange regarding Notice of Court Convened General Meeting to be held on August 17, 2026, to consider and approve the Scheme of Amalgamation between Alkem Laboratories Limited and Adroit Biomed Limited.
Alkem Laboratories Limited
Alkem Laboratories Limited has informed the Exchange about a Copy of Newspaper Publication regarding the 52nd Annual General Meeting to be held through video conferencing (VC)/other audio visual means (OAVM) on 27th August, 2026.
Alkem Laboratories Limited
Alkem Laboratories Limited has received favourable Orders-in-Appeal from the Commissioner of Income Tax, Appeal – 47, Mumbai, deleting disallowances made under section 80-IE of the Income-tax Act, 1961, involving a tax amount of Rs. 660.77 Crores. The orders were received on 30th June, 2026.
Alkem Laboratories Limited
Alkem Laboratories Limited has informed the Exchange about a newspaper advertisement inviting shareholders to submit claims for unclaimed/unpaid Final Dividend for FY 2018-2019 and subsequent years, failing which shares would be transferred to Investor Education and Protection Fund Authority.
Alkem Laboratories Limited
Alkem Laboratories Limited has informed the Exchange about the schedule of an Analyst / Institutional Investor meeting to be held on 6th July, 2026, in Mumbai.
Alkem Laboratories Limited
Alkem Laboratories Limited has informed the Exchange about the schedule of an Analyst/Institutional Investor meeting to be conducted on 03rd July, 2026, for TA Associates.
Alkem Laboratories Limited
Alkem Laboratories has informed the Exchange about an update on its acquisition of Occlutech Holding AG, a Swiss company, through its wholly-owned subsidiary Alkem Medtech Private Limited. The company has executed a First Supplementary Agreement to the Share Purchase Agreement dated 6th March, 2026, with the selling shareholders of Occlutech.
Alkem Laboratories Limited
Alkem Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.